Market capitalization | $37.31m |
Enterprise Value | $-28.22m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 4.34 |
EV/Sales (TTM) EV/Sales | -52.26 |
P/S ratio (TTM) P/S ratio | 69.09 |
P/B ratio (TTM) P/B ratio | 0.43 |
Revenue growth (TTM) Revenue growth | 92.86% |
Revenue (TTM) Revenue | $540.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Apr '24 |
+/-
%
|
||
Revenue | 0.54 0.54 |
93%
93%
|
|
Gross Profit | 0.28 0.28 |
40%
40%
|
|
EBITDA | -11 -11 |
34%
34%
|
EBIT (Operating Income) EBIT | -12 -12 |
33%
33%
|
Net Profit | -29 -29 |
96%
96%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. The Real Estate segment refers to the real estate holdings. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals. The company is headquartered in Newark, NJ.
Head office | United States |
CEO | William Conkling |
Employees | 14 |
Founded | 2017 |
Website | www.rafaelholdings.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.